Get the Stockscreener App
3.94
1.03%
0.04
After Hours:
3.94
Trevi Therapeutics Inc Stock (TRVI) Forecast
The Trevi Therapeutics Inc (TRVI) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $0.552, representing a -85.99% decrease from the current price of $3.94. The highest analyst price target is $1.0437, and the lowest is $0.0603.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month TRVI Price Target
Average 2.0057
(-49.09% Downside)
Is Trevi Therapeutics Inc (TRVI) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 52.69 | Neutral |
| STOCH(9,6) | 75.66 | Neutral |
| STOCHRSI(14) | 86.36 | Sell |
| MACD(12,26) | 0.0429 | Sell |
| ADX(14) | 19.12 | Neutral |
| William %R | -21.72 | Neutral |
| CCI(14) | 17.76 | Neutral |
Buy: 0
Sell: 2
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
3.8615
Buy
|
3.9053
Buy
|
| MA20 |
3.9663
Sell
|
3.895
Buy
|
| MA50 |
3.6021
Buy
|
3.6972
Buy
|
| MA100 |
3.3699
Buy
|
3.445
Buy
|
| MA200 |
3.0803
Buy
|
3.0789
Buy
|
Buy: 9
Sell: 1
Neutral: 0
Summary: Buy
According to our latest analysis, TRVI could be considered a Strong Buy, with 17 technical analysis indicators signaling 9 Buy signals, 3 signaling Sell signals and 5 Neutral signals. This might be a good time to open fresh positions on TRVI, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 52.69 indicates that TRVI is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 75.66 indicates that TRVI is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 86.36 indicates that TRVI is oversold. This suggests that TRVI price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 19.12 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 17.76 indicates that TRVI is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term TRVI price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Trevi Therapeutics Inc financial reports and earnings history, Trevi Therapeutics Inc (TRVI) stock could reach $1.6959 by 2030, $6.0701 by 2040 and $16.56 by 2050. See the projected annual prices until 2050 of the Trevi Therapeutics Inc stock below:
- Trevi Therapeutics Inc (TRVI) is expected to reach an average price of $3.266 in 2035, with a high prediction of $3.006 and a low estimate of $2.8023. This indicates an $-17.11% rise from the last recorded price of $3.94.
- Trevi Therapeutics Inc (TRVI) stock is projected to chart a bullish course in 2040, with an average price target of $4.4118, representing an $11.97% surge from its current level. The forecast ranges from a conservative $5.2419 to a sky-high $6.0701.
- Our analysts predict Trevi Therapeutics Inc (TRVI) to jump 158.83% by 2045, soaring from $9.2925 to an average price of $10.20, potentially reaching $10.22. While $9.2925 is the low estimate, the potential upside is significant.
- Trevi Therapeutics Inc (TRVI) stock is expected to climb by 2050, reaching an average of $15.38, a $290.32% jump from its current level. However, a wide range of estimates exists, with high and low targets of $16.56 and $15.75, respectively, highlighting the market's uncertainty.
Trevi Therapeutics Inc Stock (TRVI) Year by Year Forecast
Trevi Therapeutics Inc Stock (TRVI) Price Forecast for 2025
Trevi Therapeutics Inc Stock (TRVI) is expected to reach an average price of $2.0057 in 2025, with a high prediction of $3.9687 and a low estimate of $0.0426. This indicates an -49.09% fall from the last recorded price of $3.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $0.1337 | $0.0603 | $1.0437 | -96.61% |
| April, 2025 | $1.6061 | $0.0558 | $1.5081 | -59.24% |
| May, 2025 | $2.0479 | $2.1379 | $1.8679 | -48.02% |
| June, 2025 | $1.8898 | $2.0237 | $1.8118 | -52.04% |
| July, 2025 | $0.6605 | $0.7396 | $1.7847 | -83.24% |
| August, 2025 | $1.2286 | $0.3286 | $3.8586 | -68.82% |
| September, 2025 | $0.0933 | $0.1406 | $1.4106 | -97.63% |
| October, 2025 | $0.8731 | $0.0426 | $3.9687 | -77.84% |
| November, 2025 | $0.405 | $0.565 | $0.6911 | -89.72% |
| December, 2025 | $1.1548 | $0.5429 | $0.7846 | -70.69% |
Trevi Therapeutics Inc Stock (TRVI) Price Forecast for 2026
The predicted value for Trevi Therapeutics Inc (TRVI) in 2026 is set at an average of $1.6865. Estimates vary from a peak of $2.3108 to a trough of $1.0622, indicating an -57.20% surge from the present price of $3.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $1.2416 | $1.1407 | $1.0933 | -68.49% |
| February, 2026 | $1.4185 | $1.2846 | $1.2025 | -64.00% |
| March, 2026 | $1.2203 | $1.4103 | $1.2864 | -69.03% |
| April, 2026 | $1.1001 | $1.0622 | $0.8702 | -72.08% |
| May, 2026 | $1.372 | $1.492 | $1.394 | -65.18% |
| June, 2026 | $1.4638 | $1.4159 | $1.2759 | -62.85% |
| July, 2026 | $1.9536 | $1.7601 | $1.8236 | -50.42% |
| August, 2026 | $1.7355 | $1.8515 | $1.8516 | -55.95% |
| September, 2026 | $1.8053 | $1.8073 | $1.6653 | -54.18% |
| October, 2026 | $1.8271 | $2.0071 | $1.7957 | -53.63% |
| November, 2026 | $2.149 | $1.9651 | $2.0282 | -45.46% |
| December, 2026 | $2.3488 | $2.197 | $2.3108 | -40.39% |
Trevi Therapeutics Inc Stock (TRVI) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Trevi Therapeutics Inc (TRVI) is $1.4865, with a high forecast of $2.9219 and a low forecast of $0.051. This indicates an -62.27% decrease from the last price of $3.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $2.4507 | $2.4627 | $2.4007 | -37.80% |
| February, 2027 | $2.5925 | $2.5266 | $2.4425 | -34.20% |
| March, 2027 | $2.8985 | $2.6584 | $2.6923 | -26.43% |
| April, 2027 | $2.8255 | $2.8158 | $2.7973 | -28.29% |
| May, 2027 | $2.876 | $2.8816 | $2.8381 | -27.00% |
| June, 2027 | $2.1758 | $2.8184 | $2.9219 | -44.78% |
| July, 2027 | $1.1877 | $1.3477 | $1.6618 | -69.86% |
| August, 2027 | $0.000476 | $0.1995 | $1.0256 | -99.99% |
| September, 2027 | $0.8893 | $0.7175 | $0.9634 | -77.43% |
| October, 2027 | $1.2112 | $0.8753 | $0.8373 | -69.26% |
| November, 2027 | $0.767 | $0.343 | $0.8791 | -80.53% |
| December, 2027 | $0.9872 | $0.051 | $1.5606 | -74.95% |
Trevi Therapeutics Inc Stock (TRVI) Price Forecast for 2028
In 2028, Trevi Therapeutics Inc (TRVI) is projected to reach an average price of $0.5732, with a high projection of $1.1436 and a low estimate of $0.00266. This indicates an -85.45% fall from the last price of $3.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $0.1353 | $0.0537 | $0.9875 | -96.57% |
| February, 2028 | $1.4865 | $0.00266 | $1.1436 | -62.27% |
| March, 2028 | $0.9864 | $1.0164 | $1.1375 | -74.97% |
| April, 2028 | $1.0982 | $1.0193 | $0.8923 | -72.13% |
| May, 2028 | $1.068 | $0.7901 | $0.8862 | -72.89% |
| June, 2028 | $0.4799 | $0.5599 | $0.881 | -87.82% |
| July, 2028 | $0.3017 | $0.4538 | $0.2858 | -92.34% |
| August, 2028 | $1.0115 | $0.4256 | $0.2915 | -74.33% |
| September, 2028 | $0.8534 | $0.8634 | $0.7775 | -78.34% |
| October, 2028 | $0.6248 | $0.00737 | $0.8848 | -84.14% |
| November, 2028 | $0.305 | $0.1368 | $0.7168 | -92.26% |
| December, 2028 | $0.1069 | $0.00893 | $0.4611 | -97.29% |
Trevi Therapeutics Inc Stock (TRVI) Price Forecast for 2029
The 2029 price forecast for Trevi Therapeutics Inc Stock (TRVI) is $1.0837 on average, with a high prediction of $2.0328 and a low estimate of $0.1347. This represents an -72.49% decrease from the previous price of $3.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $0.0567 | $0.1467 | $0.1028 | -98.56% |
| February, 2029 | $0.1586 | $0.1347 | $0.0586 | -95.98% |
| March, 2029 | $0.0096 | $0.1645 | $0.0296 | -99.76% |
| April, 2029 | $0.2622 | $0.2062 | $0.2072 | -93.34% |
| May, 2029 | $0.9221 | $0.5461 | $0.6421 | -76.60% |
| June, 2029 | $1.0739 | $1.07 | $1.0339 | -72.74% |
| July, 2029 | $0.7958 | $0.8058 | $0.972 | -79.80% |
| August, 2029 | $0.6556 | $0.6556 | $0.6987 | -83.36% |
| September, 2029 | $0.4626 | $0.3726 | $1.1926 | -88.26% |
| October, 2029 | $1.6228 | $0.4146 | $2.0328 | -58.81% |
| November, 2029 | $0.9159 | $0.431 | $1.6948 | -76.75% |
| December, 2029 | $2.55 | $0.543 | $1.243 | -35.28% |
Trevi Therapeutics Inc Stock (TRVI) Price Forecast for 2030
Trevi Therapeutics Inc Stock (TRVI) is expected to reach an average price of $4.3098 in 2030, with a high forecast of $7.1459 and a low forecast of $1.4737. This signifies an +9.39% surge from the last price of $3.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $3.1496 | $1.4737 | $1.6959 | -20.06% |
| February, 2030 | $3.2033 | $3.2015 | $2.7533 | -18.70% |
| March, 2030 | $5.517 | $4.1892 | $4.0711 | +40.03% |
| April, 2030 | $5.572 | $5.8107 | $5.4589 | +41.42% |
| May, 2030 | $5.7903 | $5.7926 | $5.7003 | +46.96% |
| June, 2030 | $6.494 | $6.1663 | $6.1485 | +64.82% |
| July, 2030 | $5.9037 | $6.0688 | $7.1459 | +49.84% |
| August, 2030 | $6.2274 | $6.5582 | $6.0857 | +58.05% |
| September, 2030 | $4.6511 | $5.853 | $6.1792 | +18.05% |
| October, 2030 | $4.6107 | $4.9407 | $4.4629 | +17.02% |
| November, 2030 | $7.1994 | $4.5866 | $4.7644 | +82.73% |
| December, 2030 | $6.9581 | $7.0681 | $6.3162 | +76.60% |
3.95%
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):